| Metric | Value (₹ Cr) | Q1 FY27 | Q2 FY26 |
|---|---|---|---|
| Revenue | 461.47 | 10.6% | 1.3% |
| Total Income | 495.51 | 9.2% | 7.4% |
| Expenditure | 445.57 | 9.9% | 11.4% |
| PBT | 49.94 | 2.6% | 18.3% |
| Net Profit | 37.37 | 38.5% | 13.7% |
| OPM | 62.90% | 1.78pp | 0.34pp |
| NPM | 7.54% | 5.83pp | 1.85pp |
| EPS | 2.45 | 38.3% | 35.4% |
Disbursement surge masks PAT decline amid Profectus merger accounting
The verdict, the claims that held up, the sharpest analyst exchanges, and the risks — the earnings call, decoded from the transcript.
Hold
confidence 6/10
Grade C
Operating-expense guidance ₹490 Cr reaffirmed and tracking. ROA 3.0–3.5% by FY29 also reaffirmed. But Q2 PAT underperformed on QoQ basis (–44.9%); mix shift to lower-revenue, higher-yield business model is headwind to near-term profitability.
Cautiously Optimistic
next 1–2 quarters
Optimistic
multi-year
Management executed a courageous Feb 2026 pivot to high-growth, high-yield lending (LAP, GROx). Disbursements and focus-book growth are strong (77% and 42–22% YoY). But delivered Q2 PAT fell 13.7% YoY (and 44.9% QoQ) due to portfolio mix shift and merger accounting. The Profectus merger (NCLT hearing Nov 20) is creating reported-number volatility, and market values stock at 0.4x adjusted book. Key risk: execution of 3.0–3.5% ROA by FY29 assumes sustained focus-business CAGR, opex discipline, and credit-loss containment.
₹461.5 Cr
Revenue · +1.3% YoY₹37.4 Cr
Reported PAT · −13.7% YoYCompressing
Margins · vs guidance: MixedDid the claims hold up?
Disbursements strong at ₹3,159 Cr (77% YoY)
METDelivered Q2 revenue only ₹461.5 Cr, +1.3% YoY; mix shift to higher-yield, lower-volume lending
Operating cost down 7% YoY to ₹127.2 Cr, on track for ₹490 Cr FY27
METINR 127.2 Cr confirmed; 4Q annualized ~₹509 Cr aligns with guidance
Focus businesses (LAP+GROx) now 53% of AUM, targeting 87% by FY29
METLAP ₹4,268 Cr (+42% YoY), GROx ₹3,661 Cr (+22% QoQ); defocused shrinking as planned
PAT up 17% YoY, margin expansion ahead
MISSDelivered PAT ₹37.4 Cr, down 13.7% YoY; PBT ₹68.3 Cr up 12%, but PAT compressed by tax timing and merger accounting
Earnings quality
What changed since the last call
Profectus merger impact on reported financials
NewFeb 2026: Board approved merger. Nov 2026: NCLT approval imminent. Creates ₹120+ Cr one-time income/expense adjustments. Pro forma equity net worth ₹2,454 Cr vs reported ₹195 Cr/share.
Focus-business portfolio mix accelerated
UpgradeQ2: LAP+GROx now 53% of AUM (target 87% by FY29). Sep 2025 baseline: 32%. LAP +42% YoY to ₹4,268 Cr; GROx +22% QoQ to ₹3,661 Cr. Guidance on 25% CAGR is being beaten.
Operating-cost discipline continued
NeutralQ2 opex ₹127.2 Cr (–7% YoY); Q4 FY26 was ₹203 Cr. FY27 annual guidance ₹490 Cr (~₹122 Cr/qtr) is on track.
Defocused-book wind-down depressing revenue growth
DowngradeQ2 revenue only ₹461.5 Cr (+1.3% YoY) vs disbursement momentum +77%, due to rundown of high-disbursement, low-yield legacy portfolio. This is intentional but masks underlying business growth.
The Q&A
Analysts (Shailendra Soodh, Parth, Rajendra Jain, Piyush Bothra) pressed hard on GROx provision adequacy (coverage 45%, acknowledged 70–75% for secured LAP), end-of-life PE share supply, GROx credit risk (daily monitoring, 25 months observed), and rate sensitivity (15–20 bps impact from hike). Management held up, answering directly. Only brief voice-clarity issue on one question.
GROx provision & growth — Shailendra Soodh
AnsweredNo. GROx credit cost ~2% of AUM portfolio. Unsecured merchant lending; typically 1.4% NPA. 45% PCR is adequate; LAP has 70–75%.
PE shareholder supply — Parth, Zen Wealth
PartialYes, ongoing. IFU 15.5%, ADV ~9.5% still hold shares. They stepped down from Board but are public shareholders; no immediate overhang concern.
GROx credit risk detail — Parth
Answered25 months operating (Sep 2024 start). Seen 2 full cycles. Daily transaction monitoring. Short tenure (12–13 months). Behavioral underwriting via transaction history. Repayment of ~₹800 Cr monthly. Confidence in controls.
Interest-rate hedging — Parth
Answered50–50 fixed-floating. Floating mostly MCLR-linked, 1-year reset. Expect 15–20 bps impact from recent hikes. Cost of borrowing already up 5 bps QoQ.
Rating upgrade timeline — Parth
AnsweredAgencies engaged. Plan set in Feb. Expected by end of CY26. Two quarters done, hoping to continue performance and upgrade sooner.
Revenue recognition impact — Piyush Bothra, GMO PG
AnsweredAll past upfront income on co-lending now spread over expected tenure (observed behavioral). H1 reversals ₹120.5 Cr (one-time). Going forward, co-lending income on behavioral tenure; no change to DA+co-lending interest. Other income forms derecognition gain (not part of core revenue).
Profit recovery horizon — Rajendra Jain
AnsweredManagement commitment: quarter-on-quarter profit growth ahead. Both focus businesses executing well. Merger completes next step. Defocused book declining, higher-yield portfolio growing. Direct path to 3–3.5% ROA by FY29.
Guidance
FY27 AUM expected flat per prior call; now 23% YoY growth, mix shift to 53% focus books
HighPrior guidance was AUM flat due to portfolio mix shift. Delivered better—23% total AUM growth with focus books accelerating. Guidance reframed in terms of focus-business composition (87% by FY29).
FY29 ROA pathway to 3.0–3.5% from normalized 2.1% Q1 base (pro forma 2.7% H1)
HighMechanism: focus businesses at 87% portfolio (vs 53% today) with 18.7% blended yield, opex held flat at ₹490 Cr annual (leverage to AUM), interest-income growth, credit cost ~2% AUM. Reaffirmed this quarter.
Operating expense guidance ₹490 Cr annual run-rate; Q2 ₹127.2 Cr tracking
HighFY26 opex was higher (~₹203 Cr Q4) due to merger costs and legacy overhead. FY27 ₹490 Cr (~₹122.5 Cr/qtr) is sustainable baseline as focus-business mix improves.
Risks the call surfaced
Merger accounting complexity
HighProfectus goodwill ₹308 Cr, acquisition costs, excess interest-spread remeasurement (₹266 Cr adjustment), and behavioral-tenure income recognition are creating ₹120+ Cr one-time items. Reported Q2 PAT ₹37.4 Cr opaque on standalone vs. merged basis.
GROx merchant-lending credit risk
MediumGROx is unsecured small-retailer lending (daily/weekly repayment). Only 25 months operating; seen 2 full cycles. External shocks (Suez war, Middle East tensions) briefly caused defaults. Portfolio yield 26% is high, but loss severity if concentration hits could spike.
LAP & GROx portfolio concentration
MediumTwo focus businesses now 53% of AUM, targeting 87% by FY29. If macro downturn hits small-business lending (LAP & merchant lending), portfolio-wide credit losses could spike. Currently diversifying via branch expansion & partner platform breadth.
Interest-rate sensitivity
Medium50–50 fixed-floating borrowing mix. Floating mostly MCLR-linked with 1-year reset. Recent RBI hikes will flow through in 12 months. Finance cost expected to rise 15–20 bps from accumulated hikes.
Profectus regulatory approval
MediumNCLT final sanction hearing scheduled Nov 20, 2026. Merger depends on approval. Delay or rejection would leave Profectus integration unresolved and create accounting/tax complexity.
Management
Score 7/10. Transparent on accounting adjustments, risks, and market skepticism. Candid about Feb 2026 pivot (stopped volatile co-lend model, running down defocused book). Not overselling. One voice-clarity issue on a question but otherwise articulate. Delivered 77% disbursement growth and 42% LAP CAGR in 9 months post-pivot. Focus-business mix rose from 32% to 53%. Operating cost down 7% YoY. But reported PAT fell 13.7% YoY due to deliberate mix shift to lower-revenue, higher-yield business. Track record mixed: guidance reaffirmed, but near-term numbers underperformed.
1 · Nov 20, 2026
Profectus NCLT final sanction hearing; merger completion frees reported-number volatility
2 · Q3 FY27
Management claims "every quarter should be better"—test profit recovery post-merger as reversals dry up
3 · End CY26
Credit-rating agencies expected to upgrade (plan set in Feb); new rating could re-rate equity
Key risk: execution of 3.0–3.5% ROA by FY29 assumes sustained focus-business CAGR, opex discipline, and credit-loss containment.
Disbursements surge 77%, profit falls 44%: the pivot that spooked the market
Management executed a deliberate portfolio pivot from volume-heavy defocused lending to high-yield focused businesses. The strategy is working—but the reported numbers tell the opposite story, and the market has voted with its feet.
₹37.4 Cr
-13.7% YoY, -44.9% QoQ
₹68.3 Cr
+12% YoY
Defocused → Focused
32% baseline → 53% focus
₹3,159 Cr
+77% YoY momentum
The quarter in one tension
Ugro Capital reported Q2 revenue of ₹461.5 Cr, essentially flat (+1.3% YoY), and PAT of ₹37.4 Cr, down 13.7% YoY and a stunning 44.9% QoQ. Yet the company disbursed ₹3,159 Cr in the quarter—77% more than a year ago—and the two growth businesses that management has been betting on (Emerging Market LAP and GROx embedded merchant finance) are firing on all cylinders. The profit miss was not a failure of origination or cost control. It was a deliberate trade: management shifted the portfolio from high-volume, low-yield defocused lending to high-yield, lower-volume focused lending. Revenue per rupee of disbursement fell as a result. That shift is rational and strategic. But the reported P&L is now noisy with one-time merger accounting adjustments (the Profectus integration is pending NCLT final approval on Nov 20), and the market has lost patience.
Where the profit went
Reported PAT of ₹37.4 Cr sits below PBT of ₹68.3 Cr (+12% YoY) due to tax timing and merger-related adjustments. More important: the company's interest income rose 20% YoY to ₹385.5 Cr (portfolio yield now 18.7%, up 108 basis points), but other income was held flat by ₹51.8 Cr in co-lending reversals as management shifted income recognition to behavioral tenure (a conservative accounting move). Those reversals are temporary; as the defocused book winds down, reversal headwinds will abate. But in Q2, they masked the strength in core lending income.
What changed on this call
Portfolio rebalance accelerated. In nine months, management shifted the focus-business mix from 32% of AUM (baseline, Sep 2025) to 53% as of Q2. Emerging Market LAP grew 42% YoY to ₹4,268 Cr; GROx grew 22% QoQ to ₹3,661 Cr. The defocused book (legacy, high-volume, low-yield co-lending portfolio) is winding down as planned, with repayments and foreclosures running ahead of schedule. That is why total AUM grew only 23% YoY despite the two focus businesses shooting forward—the defocused rundown offsets.
Disbursement engine humming. ₹1,000+ Cr in disbursements every month in Q2 (July, Aug, Sept) is the highest monthly run-rate in the company's history. LAP is disbursing via 317 branches across 13 states with 1.8k+ sales staff; GROx is embedded in payment-app ecosystems (PhonePe, Paytm, BharatPay) and is touching 4.1 lakh active merchants. Neither strategy is a hope—it is live.
Operating cost stayed disciplined. Q2 opex of ₹127.2 Cr is down 7% YoY and down 37% from Q4 FY26 (₹203 Cr, which was inflated by merger costs). The FY27 annual guidance of ₹490 Cr is tracking—roughly ₹122.5 Cr per quarter. That is opex leverage as AUM grows.
Profectus merger pending final approval. The NCLT is scheduled to hear the scheme on Nov 20. Once approved, the merger closes, and the reported-number volatility from goodwill remeasurement (₹308 Cr), acquisition costs (₹266 Cr), and excess-interest-spread revaluation will stabilize. Until then, expect continued one-time adjustments. Management has disclosed a pro forma net worth of ₹2,454 Cr vs. reported ₹195 Cr per share, showing the magnitude of the accounting bridge.
Disbursements strong at ₹3,159 Cr (77% YoY)
₹3,159 Cr, +77% YoY confirmed
Supported
Operating cost down 7% YoY to ₹127.2 Cr; on track for ₹490 Cr FY27
₹127.2 Cr confirmed; ₹490 Cr annual tracking ~₹122 Cr/qtr
Supported
Focus businesses (LAP+GROx) now 53% of AUM, targeting 87% by FY29
LAP ₹4,268 Cr (+42% YoY), GROx ₹3,661 Cr (+22% QoQ); 53% composition confirmed
Supported
PAT momentum driving margin expansion ahead
Delivered PAT ₹37.4 Cr, down 13.7% YoY; PBT up 12% but PAT compressed by tax and merger adjustments
Contradicted—near-term margin under pressure due to mix shift and merger accounting
How the street sees it
The market has moved decisively against UGRO. FII ownership has cratered from 29.32% in Q1 FY26 to 5.45% in Q1 FY27—a withdrawal of 2,387 basis points. The stock trades at ₹68.02, down 78% from its all-time high of ₹312.7, and sits below all major moving averages (SMA20 ₹73.8, SMA50 ₹79.17, SMA200 ₹97.86). Book value (pro forma) is ₹2,454 Cr; market cap is ₹1,130 Cr—the stock is priced at 0.4x adjusted book. RSI stands at 30.3, technically oversold but not reversing. Volume is normal, not panic capitulation.
What spooked the FII: (1) the reported profit miss, which hit hardest on a QoQ basis (–44.9%), compounding the perception that the pivot had backfired; (2) confusion around merger accounting and the opacity of pro forma vs. reported numbers; (3) GROx's youth as a business—only 25 months old, and external shocks (Middle East tensions in Aug 2025) briefly spiked merchant defaults, reminding the market that short-tenor merchant lending has tail risk; (4) the execution bet itself—management's Feb 2026 pivot was aggressive, and the near-term reported-number deterioration tested patience before the strategy could deliver upside. The market interpreted the pivot as a sign of distress, not opportunity.
Ranked risks for a holder
Merger accounting complexity creates reported-number opacity through FY28
High₹120+ Cr in one-time adjustments (goodwill, reversals, fair-value remeasurement) will create periodic earnings surprises until the Profectus integration fully closes. Investors discount opaque earnings; the 0.4x book valuation reflects this.
GROx merchant-lending credit risk if macro downturn hits small retailers
HighGROx is only 25 months old and has seen two full cycles. Portfolio yield is 26%, but unsecured merchant lending can see rapid loss severity if economic shock hits. Daily monitoring and 70–75% PCR are mitigants, but a 1% swing in credit cost could swing PAT ₹35+ Cr.
Portfolio concentration in focus businesses (53% and targeting 87% by FY29)
MediumBoth LAP and GROx target small-business lending. Sector-wide shock (credit freeze on SME lending, rate shock, or policy change) could spike credit losses portfolio-wide. Defocused book rundown limits diversification for 2–3 years.
Interest-rate sensitivity; 50–50 fixed-floating mix with 1-year MCLR reset
MediumRecent RBI hikes will flow through in 12 months; management expects 15–20 basis points headwind to NIM. Cost of borrowing already up 5 basis points QoQ. If lending rates do not reset in lockstep, net interest margin compresses.
Profectus NCLT approval delay or rejection
MediumFinal sanction hearing scheduled Nov 20. Delay would extend reported-number volatility and leave balance-sheet integration incomplete. Rejection would force recapitalization and re-strategy; highly unlikely but not zero risk.
Disbursements momentum: ₹1,000+ Cr monthly, highest in company history
Focus-business CAGR targets being beaten (LAP 42% YoY vs. 20–30% target)
Operating-cost discipline: 7% YoY decline, on track for FY27 guidance
Interest income growth 20% YoY; portfolio yield expanding (18.7%, up 108 bps)
Reported PAT down 44.9% QoQ—a severe miss on near-term basis
Revenue growth only 1.3% YoY despite 77% disbursement growth—mix-shift headwind is real
GROx only 25 months old; credit risk unproven through full cycle
Merger accounting opacity creates reported-number risk through FY28
FII exodus (–2,387 bps in 12 months) signals conviction bearishness
Valuation at 0.4x pro forma book is deep discount; suggests market pricing in scenario risk
1 · Profectus NCLT final sanction (Nov 20, 2026)
Merger approval will unlock reported-number clarity and end goodwill/fair-value remeasurement volatility. Market re-rates equity heavily on visibility; if Nov 20 hearing clears, expect re-rating rally in subsequent weeks.
2 · Q3 FY27 organic profit recovery
Management committed "every quarter should be better." Q3 will be the first real test post-Profectus. If organic profit (ex reversals, merger adjustments) grows QoQ and inflects upward, the bear case weakens materially. If PAT remains flat or declines, execution doubt hardens.
3 · Credit-rating upgrade by end CY26
Agencies are engaged (plan set in Feb 2026). Rating upgrade would lower UGRO's borrowing cost, expanding NIM. Upgrade also signals third-party validation of the pivot. If upgrade clears, cost-of-borrowing pressure eases and ROA target credibility rises.
4 · Focus-business CAGR tracking through FY29
LAP target 20–30% annual CAGR (Q2 actual 42% YoY—well ahead). GROx target 35–40% (Q2 actual 22% QoQ—tracking on annualized basis; new business at 25 months). Both are beating current guidance. Monitor whether momentum is sustainable through macro cycles. This is the ultimate credibility test for the FY29 ROA 3.0–3.5% pathway.
Ugro Capital is in the middle of a portfolio pivot that will take 18–24 months to fully play out. The strategy is sound—high-yield, lower-volatility lending beats the old co-lend trap. Execution metrics (disbursements, focus-book growth, opex discipline) are on track. But reported profit has deteriorated sharply, merger accounting is clouding the picture, and the market has voted with its feet—FII down 2,387 basis points, stock down 78%, valuation at 0.4x book.
For a holder or prospective buyer, the critical question is not whether the strategy is good—it is—but whether management can deliver organic profit growth while integration headwinds ease. Profectus NCLT approval on Nov 20 is the first gate. Q3 organic PAT inflection is the second. If both clear, the 0.4x valuation will look generous in hindsight. If either wobbles, the market's pessimism is justified.
The single number to track from here is organic PAT growth on a QoQ basis (excluding merger adjustments and reversals). That will tell you whether the pivot is working or whether reported numbers are about to disappoint for a third or fourth quarter. Until that turns positive, the near-term tape stays under pressure, regardless of the long-term thesis.